paclitaxel and s 1033
paclitaxel has been researched along with s 1033 in 8 studies
Research
Studies (8)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bai, Y; Ding, K; Feng, Y; Lang, X; Leng, F; Li, Y; Liu, J; Long, H; Lu, X; Luo, J; Pan, J; Pan, X; Ren, X; She, M; Tu, Z; Wang, D; Wen, D; Zhang, F; Zhang, Z; Zhuang, X | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ashby, CR; Chen, A; Chen, X; Chen, ZS; Hopper-Borge, E; Kuang, YH; Lei, Y; Ouyang, J; Shen, T; Tiwari, AK; Zhou, Y | 1 |
| Bertomeu, T; Bucur, O; Dewar, R; Goganau, I; Khosravi-Far, R; Pennarun, B; Petrescu, SM; Stancu, AL | 1 |
| Alkatout, I; Jonat, W; Maass, N; Mundhenke, C; Rath, K; Schem, C; Weigel, MT; Wenners, AS | 1 |
| Alberti, P; Arnold, WD; Cavaletti, G; Chen, M; Chiorazzi, A; Chodisetty, V; Costa, O; de Bruijn, P; Florea, T; Gibson, AA; Hong, KW; Hu, S; Huang, KM; Leblanc, AF; Lustberg, MB; Mathijssen, RH; Pioso, MS; Reinbolt, RE; Sparreboom, A; Sprowl, JA; Sucheston-Campbell, LE | 1 |
| Alcoser, SY; Borgel, S; Bottaro, DP; Chen, AP; Chen, L; Chuaqui, R; Doroshow, JH; Ferry-Galow, KV; Hollingshead, MG; Kinders, RJ; Konaté, MM; Kummar, S; Lawrence, SM; Makhlouf, HR; Miller, SB; Navas, T; Parchment, RE; Rubinstein, L; Srivastava, AK; Subramanian, J; Vilimas, T; Voth, AR; Wilsker, DF | 1 |
| Brors, B; Haibe-Kains, B; Kurilov, R | 1 |
Reviews
1 review(s) available for paclitaxel and s 1033
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Other Studies
7 other study(ies) available for paclitaxel and s 1033
| Article | Year |
|---|---|
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Biological Availability; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Magnetic Resonance Spectroscopy; Models, Molecular; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Spectrometry, Mass, Electrospray Ionization | 2013 |
Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).
Topics: Antineoplastic Agents; Benzamides; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Models, Chemical; Multidrug Resistance-Associated Proteins; Neoplasms; Paclitaxel; Piperazines; Pyrimidines; Tetrazolium Salts; Thiazoles | 2009 |
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.
Topics: Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Heterocyclic Compounds, 2-Ring; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pteridines; Pyrazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles | 2013 |
Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Ovarian Neoplasms; Paclitaxel; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2014 |
OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Genotype; HEK293 Cells; Humans; Hyperalgesia; Inhibitory Concentration 50; Liver-Specific Organic Anion Transporter 1; MCF-7 Cells; Mice; Mice, Inbred DBA; Mice, Knockout; Mice, Transgenic; Organic Anion Transporters; Paclitaxel; Peripheral Nervous System Diseases; Phenotype; Pyrimidines | 2018 |
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Biomarkers, Tumor; Biopsy, Large-Core Needle; Cadherins; Carcinoma; Cell Line, Tumor; Cell Plasticity; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Indazoles; Male; Mice; Neoplastic Stem Cells; Paclitaxel; Pyrimidines; Sulfonamides; Vimentin; Xenograft Model Antitumor Assays | 2020 |
Assessment of modelling strategies for drug response prediction in cell lines and xenografts.
Topics: Animals; Biomarkers, Pharmacological; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Imidazoles; Indoles; Lapatinib; Machine Learning; Mice; Neoplasms; Organ Specificity; Paclitaxel; Piperazines; Prognosis; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |